drugset / Trial / NCT02835794
A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and establish the maximum tolerated dose (MTD) of omacetaxine in combination with azacitidine and G-CSF in patients with relapsed and/or refractory MDS.
Timeline
- Start
- 2016-08
- Primary completion
- 2018-12
- Completion
- 2018-12
Outcome
Outcome not reported
Stopped (Business): “Lack of funding to support clinical trial”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omacetaxine | Unknown | — | Subcutaneous |
| Background | Azacitidine | Other / unclassified | 50 mg/m2 | Subcutaneous |
| Background | G-CSF | Unknown | 5 ug/kg | Subcutaneous |